
How Claims Data Volatility
Is Impacting Biopharma:
A 2025 Industry Snapshot

The data volatility ripple effect
69% of biopharma leaders reported experiencing disruptions in
their real-world claims data in the past year. The volatility leads to
flawed analytics, delayed timelines, and lost productivity.
A new survey sponsored by McKesson Compile™ uncovers how
volatility in real-world claims data is impacting commercialization —
and how teams are adapting.
Snapshot: Erroneous insights
The graphic below provides a preview of the analysis featured
in the report. Here, 73% of respondents claimed data issues led
to false insights. Among them, 86% were forced to reverse a
business decision. This is only a glimpse into the consequences
of data volatility.

Download the report
Get the full report to explore:

Where data volatility
is hitting commercial
teams the hardest
and why it often
goes undetected

How disruptions are
delaying decisions,
increasing rework,
and introducing risk

What steps biopharma
leaders are taking
to strengthen data
reliability and vendor
accountability
